GlassScriptPhysician profile
Dexter A Jensen
NPI 1740465541
$2,664.31
in general payments reported to CMS, 2019-2025
13 companies · $552 in 2025
The $552 reported for 2025 was more than what 77% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $66.20 · 2021: $102 · 2022: $628 · 2023: $382 · 2024: $29.19 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $512.47 | 2019-2025 | Invega Sustenna, Invega, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $482.24 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $431.10 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $321.92 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.08 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $203.81 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $147.96 | 2022 | |
| Vanda Pharmaceuticals INC. | $73.22 | 2025 | Fanapt |
| Abbvie INC. | $60.77 | 2022-2023 | |
| Indivior INC. | $43.80 | 2019-2023 | Perseris |
| Lundbeck LLC | $32.37 | 2019 | |
| Allergan, INC. | $29.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.58 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dexter Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.